Long Term Development Agreement to Produce Reference Standard Reagents to
Advance Cancer Research
NEWARK, Del., April 3, 2008 /PRNewswire-FirstCall/ -- Strategic Diagnostics Inc. (Nasdaq: SDIX) -- a leader in providing advanced antibody products and services to the life sciences industry announced that it has been selected by Science Applications International Corporation - Frederick (SAIC-F), to develop monoclonal antibodies for the Proteomics Reagents & Resources component of the National Cancer Institute (NCI) Clinical Proteomic Technologies for Cancer initiative (CPTC). The goal of CPTC is to accelerate discovery and clinical research in cancer using an integrated approach that assesses and optimizes proteomic technology measurement capabilities and develops universally accepted metrics that identify and minimize experimental variability from run to run, instrument to instrument, and lab to lab. CPTC aims to achieve this through the optimization of existing platforms; developing innovative proteomic technologies and computational tools; and developing community reagents and resources. The Proteomic Reagents & Resources component will include SOPs, data, proteins, and well-characterized, high-quality antibodies whose performance characteristics will be conducted at an Antibody Characterization Laboratory at NCI-Frederick (NCI-F) that is part of NCI-F's Advanced Technology Program.
SDI was awarded the competitive contract to produce monoclonal antibodies that will serve as reference reagents for the scientific cancer community based on its technical strength, large-scale capacity, standardized processes, and fully integrated quality management system.
Matthew H. Knight, SDI's President and Chief Executive Officer, commented, "SDI is very proud to have been selected to become a key supplier in this large scale initiative. This award is another example of how our commitment to efficiency, quality, capacity, and expertise has positioned us as a premier supplier of comprehensive antibody services to the research community. Being selected to supply these critical tools to advance cancer research is further validation of the exceptional team and infrastructure SDI has developed. As the study of proteins increases in importance to the research community, we foresee a continued and sustained need for SDI's expertise in antibodies as they continue to be the most widely used tools for understanding the molecular dynamics underlying disease."
Under the contract, SDI will produce monoclonal antibodies for the Clinical Proteomic Technologies for Cancer Initiative of the NCI (http://proteomics.cancer.gov) and SAIC-F and the NCI will extensively characterize these reagents consistent with their mission to make available high quality reagents with baseline data.
About Strategic Diagnostics Inc.
Strategic Diagnostics Inc. (SDI) is an antibody technology company; developing, commercializing and marketing innovative and proprietary biotechnology solutions that preserve and enhance the quality of human health. SDI's antibody division supplies critical reagents used in the diagnosis of disease. The Company's new Genomic Antibody Technology(R) is gaining wide adoption in producing custom research reagents for applied proteomic research, and drug/biomarker discovery among academic, biotech and large pharmaceutical customers. The Company's SEQer(R) antibody catalog is the fastest growing collection of polyclonal antibodies for cancer research. SDI scientists are experts in the development of immunoassays and are using the Company's capacity for high throughput production of high quality antibodies to deliver content for a new generation of multiplex assays for use in biomarker discovery. For more information, visit the Company's website at http://www.sdix.com.
This news release contains forward-looking statements reflecting SDI's
current expectations. When used in this press release, the words
"anticipate", "could", "enable", "estimate", "intend", "expect", "believe",
"potential", "will", "should", "project", "plan" and similar expressions as
they relate to SDI are intended to identify said forward-looking
statements. Investors are cautioned that all forward-looking statements
involve risks and uncertainties, which may cause actual results to differ
from those anticipated by SDI at this time. Such risks and uncertainties
include, without limitation, changes in demand for products, delays in
product development, delays in market acceptance of new products, retention
of customers and employees, adequate supply of raw materials, inability to
obtain or delays in obtaining fourth party, including AOAC, or required
government approvals, the ability to meet increased market demand,
competition, protection of intellectual property, non-infringement of
intellectual property, seasonality, and other factors more fully described
in SDI's public filings with the U.S. Securities and Exchange Commission.
Company Contact: Investor Contact:
Stan Fronczkowski Hayden Communications
Chief Financial Officer Brett Maas (email@example.com)
(302) 456-6789 (646) 536-7331
|SOURCE Strategic Diagnostics Inc.|
Copyright©2008 PR Newswire.
All rights reserved